TERBUTALINE SULFATE- terbutaline sulfate tablet

Country: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

TERBUTALINE SULFATE (UNII: 576PU70Y8E) (TERBUTALINE - UNII:N8ONU3L3PG)

Disponibbli minn:

PD-Rx Pharmaceuticals, Inc.

INN (Isem Internazzjonali):

TERBUTALINE SULFATE

Kompożizzjoni:

TERBUTALINE SULFATE 5 mg

Rotta amministrattiva:

ORAL

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. 1. Tocolysis Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. [see Boxed Warning: Tocolysis . ] 2. Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.

Sommarju tal-prodott:

Terbutaline sulfate tablets, USP are packaged in bottles of 4 tablets. Descriptions of the 5 mg tablets follow: Tablets 5 mg—round, white, scored (imprinted LCI over 1311) Bottles of 4       NDC 43063-558-04 Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure Rev. 02/16

L-istatus ta 'awtorizzazzjoni:

Abbreviated New Drug Application

Karatteristiċi tal-prodott

TERBUTALINE SULFATE- TERBUTALINE SULFATE TABLET
PD-RX PHARMACEUTICALS, INC.
----------
TERBUTALINE SULFATE TABLETS, USP
RX ONLY
WARNING: TOCOLYSIS
ORAL TERBUTALINE SULFATE HAS NOT BEEN APPROVED AND SHOULD NOT BE USED
FOR ACUTE OR
MAINTENANCE TOCOLYSIS. IN PARTICULAR, TERBUTALINE SULFATE SHOULD NOT
BE USED FOR MAINTENANCE
TOCOLYSIS IN THE OUTPATIENT OR HOME SETTING. SERIOUS ADVERSE
REACTIONS, INCLUDING DEATH, HAVE
BEEN REPORTED AFTER ADMINISTRATION OF TERBUTALINE SULFATE TO PREGNANT
WOMEN. IN THE MOTHER,
THESE ADVERSE REACTIONS INCLUDE INCREASED HEART RATE, TRANSIENT
HYPERGLYCEMIA,
HYPOKALEMIA, CARDIAC ARRHYTHMIAS, PULMONARY EDEMA AND MYOCARDIAL
ISCHEMIA. INCREASED
FETAL HEART RATE AND NEONATAL HYPOGLYCEMIA MAY OCCUR AS A RESULT OF
MATERNAL ADMINISTRATION.
[SEE _CONTRAINDICATIONS, TOCOLYSIS. _]
DESCRIPTION
Terbutaline sulfate USP is a beta-adrenergic agonist bronchodilator
available as tablets of 2.5 mg (2.05
mg of the free base) and 5 mg (4.1 mg of the free base) for oral
administration. Terbutaline sulfate is ±-
α-[( _tert_ –butylamino) methyl]-3,5-dihydroxybenzyl alcohol
sulfate (2:1) (salt). The molecular formula is
(C
H
NO
)
• H
SO
and the structural formula is
Terbutaline sulfate USP is a white to gray-white crystalline powder.
It is odorless or has a faint odor of
acetic acid. It is soluble in water and in 0.1N hydrochloric acid,
slightly soluble in methanol, and
insoluble in chloroform. Its molecular weight is 548.65.
_Inactive Ingredients:_ anhydrous lactose, pregelatinized corn starch,
microcrystalline cellulose,
povidone, and magnesium stearate.
CLINICAL PHARMACOLOGY
_In vitro _and _in vivo _pharmacologic studies have demonstrated that
terbutaline exerts a preferential effect
on beta
-adrenergic receptors. While it is recognized that beta
-adrenergic receptors are the
predominant receptors in bronchial smooth muscle, data indicate that
there is a population of beta
-
receptors in the human heart, existing in a concentration between 10%
to 50%. The precise function of
these receptors has not been e